A DEXA scan is not designed to detect cancer and should never be used as a cancer screening tool. Its primary job is measuring bone mineral density to assess osteoporosis risk. That said, DEXA scans occasionally produce findings that raise suspicion of a malignancy, particularly when cancer has spread to bone or when unusual density readings prompt further investigation. Understanding what a DEXA scan can and cannot reveal about cancer helps explain both why these incidental findings matter and why they are no substitute for dedicated oncologic imaging.
What a DEXA Scan Actually Measures
DEXA stands for dual-energy X-ray absorptiometry. The scan works by passing two low-energy X-ray beams through the body at different energy levels. Because bone, fat, and lean tissue absorb these beams differently, the machine can calculate how dense your bones are at key sites, usually the hip and lumbar spine. The output is a bone mineral density (BMD) score, which clinicians compare against reference values to determine whether you have normal bone density, reduced density (osteopenia), or outright osteoporosis.
DEXA remains the gold standard for diagnosing osteoporosis, with well-established advantages over alternative bone-density techniques: its results can be interpreted using widely accepted scoring criteria, it reliably predicts fracture risk, and it can track how bone responds to treatment over time.1PubMed Central. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis Other imaging methods can provide additional detail about bone structure, but DEXA holds its central role in clinical practice.2PubMed Central. DEXA and Imaging in Osteoporosis
One important limitation is that DEXA produces a two-dimensional image. It projects a flat, front-to-back view of the scanned region and cannot assess volume the way CT or MRI can.3Oxford Academic. Imaging modalities for measuring body composition in patients with cancer: opportunities and challenges This means it cannot pinpoint a mass within a bone, distinguish a tumor from a dense calcification, or show structures behind or in front of the spine in any three-dimensional detail. It tells you how much mineral is in a given area of bone. It does not tell you why that number is what it is.
How Cancer Can Show Up on a DEXA Scan
Although DEXA is blind to most cancers, certain malignancies alter bone density in ways the scan picks up. The catch is that the scan does not identify these changes as cancer. It reports them as unexpectedly high or low BMD readings, or as visual abnormalities on the scan image that a trained radiologist might notice. The road from “something looks off on this DEXA” to “you have cancer” always runs through additional imaging and testing.
Cancers that spread to bone generally do so in one of two patterns. Some create bone-forming (osteoblastic) lesions that deposit extra mineral, making affected areas appear denser than they should be. Others create bone-destroying (osteolytic) lesions that dissolve mineral, making affected areas appear less dense. A few cancers produce a mix of both. Each pattern interacts with a DEXA scan differently.
Osteoblastic Lesions and Falsely High Readings
Prostate cancer is the classic example of a cancer that produces osteoblastic bone metastases. When these dense, bone-forming lesions land in the lumbar spine, they can drive BMD readings artificially high. Research on prostate cancer patients found that BMD values in the lumbar vertebrae were significantly higher in men with bone metastases compared to those without, while BMD at a peripheral site like the wrist showed no meaningful difference.4PubMed. Bone mineral density for patients with bone metastasis of prostate cancer: a preliminary report In other words, the metastatic deposits were artificially inflating the spine reading, creating a misleading picture of “strong” bones at that site.
This is a problem for two reasons. First, a patient who actually has osteoporosis alongside metastatic disease could receive a falsely reassuring BMD result. Second, a clinician who notices an unexpectedly high or asymmetric density reading might suspect something is wrong, but the DEXA scan alone cannot confirm the cause. A study using machine-learning classifiers found that when researchers trained algorithms specifically to flag osteoblastic metastases on DEXA images, the best-performing model achieved about 78% sensitivity and 100% specificity. But without that algorithmic help, only about 16% of patients with osteoblastic metastases in the dataset had been identified by the radiologist reading the scan in real time.5PubMed. Random forest classifiers aid in the detection of incidental osteoblastic osseous metastases in DEXA studies That gap highlights how easy it is for metastatic disease to hide in plain sight on a routine bone density scan.
Osteolytic Lesions and Unexplained Low Readings
Cancers that destroy bone, such as multiple myeloma and many types of metastatic disease, can cause localized drops in BMD. Lytic bone lesions affecting one or more vertebrae, metastatic deposits, and destructive processes like infection can all reduce the measured density in a specific area.6Seminars in Nuclear Medicine. Artifacts and Incidental Findings Encountered on Dual-Energy X-Ray Absorptiometry: Atlas and Analysis On a DEXA report, this might appear as a single vertebra with a dramatically lower score than its neighbors, or as an overall spine reading that seems worse than what the patient’s age and risk factors would predict.
Multiple myeloma is a blood cancer that frequently damages bone. Studies of myeloma patients have found significantly reduced BMD at the lumbar spine compared to what would be expected for their age and sex, with fractured vertebrae showing even more pronounced density loss. Vertebrae that had not yet fractured in those same patients also showed markedly low density, suggesting widespread skeletal involvement.7PubMed. Assessment of bone involvement in patients with multiple myeloma using bone densitometry A clinician seeing these patterns on DEXA would not diagnose myeloma from the scan alone, but the unusual findings could trigger blood work and more advanced imaging that leads to a diagnosis.
Incidental Findings Beyond Bone
Because a DEXA scan captures an image of whatever lies in the X-ray’s path, it occasionally reveals non-bone abnormalities. These are incidental findings, structures or conditions the scan was never intended to detect but that happen to be visible. Gallstones, kidney stones, calcified uterine fibroids, and vascular calcifications in the abdomen are among the most commonly spotted incidentals on DEXA images.6Seminars in Nuclear Medicine. Artifacts and Incidental Findings Encountered on Dual-Energy X-Ray Absorptiometry: Atlas and Analysis Most of these are benign, but some can mimic or mask more concerning pathology.
A large calcified mass overlying the spine, for instance, can artificially raise the BMD reading at that level, potentially obscuring real bone loss beneath it. Similarly, aortic calcification running alongside the lumbar vertebrae is a well-known source of falsely elevated spine BMD. These artifacts are important because they can confuse the osteoporosis assessment, but they are also important because occasionally the “artifact” turns out to be clinically relevant. A calcified mass in the pelvis or abdomen is not always a harmless fibroid. The radiologist’s job when reviewing a DEXA image is to flag anything unexpected, even if DEXA is not the right tool to characterize it.
Why DEXA Cannot Replace Dedicated Cancer Imaging
Even when a DEXA scan hints at something suspicious, it lacks the resolution and dimensionality to do anything more than wave a flag. CT, MRI, PET scans, and bone scintigraphy (nuclear bone scans) each offer capabilities that DEXA fundamentally cannot match.
CT provides three-dimensional, cross-sectional images that can show the exact size, shape, and location of a lesion within bone or soft tissue. MRI excels at detecting bone marrow infiltration, which is a hallmark of many cancers that have spread to the skeleton and is essentially invisible on DEXA. PET scans detect metabolically active tissue, making them especially useful for finding cancer deposits that are small or in unexpected locations. A DEXA scan’s two-dimensional projection, combined with its very low radiation dose and limited image resolution, means it simply cannot compete with these modalities for characterizing what a suspicious finding actually is.
The radiation dose of a DEXA scan is extraordinarily low. Modern total-body DEXA scans expose a patient to roughly 4 to 5 microsieverts, which is less than a single day of natural background radiation.3Oxford Academic. Imaging modalities for measuring body composition in patients with cancer: opportunities and challenges Older pencil-beam devices deliver even less at specific sites, around 1 microsievert for a spine and hip scan.8European Radiology. Radiation exposure in X-ray-based imaging techniques used in osteoporosis This negligible dose is a major advantage for repeat monitoring but also reflects how little imaging information the scan captures compared to higher-dose modalities like CT.
DEXA’s Real Role in Cancer Care
While DEXA is not a cancer-detection tool, it plays a genuine and important part in the care of people who already have cancer or have survived it. Many cancer treatments accelerate bone loss, and DEXA is the standard way to monitor that.
Hormone-blocking therapies used in breast and prostate cancer are particularly damaging to bone. Aromatase inhibitors, which suppress estrogen in postmenopausal women with breast cancer, and androgen deprivation therapy, which suppresses testosterone in men with prostate cancer, both strip away hormones that help maintain bone density. Guidelines recommend that most patients with breast or prostate cancer undergo bone-health assessment that includes DEXA scanning and fracture risk evaluation.9American Journal of Health-System Pharmacy. Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer Chemotherapy, radiation to bone-bearing areas, and prolonged corticosteroid use can also weaken the skeleton in ways that DEXA is well suited to track.
The goal here is not finding cancer. It is preventing fractures in people whose cancer treatment has put their bones at risk. A patient on aromatase inhibitors for five years may lose bone density steadily over that time, and serial DEXA scans help clinicians decide when to add bone-protective medications like bisphosphonates or denosumab.
Childhood Cancer Survivors and Long-Term Bone Health
Pediatric cancer survivors face a unique set of skeletal risks. Children and adolescents treated with radiation, particularly total body irradiation or cranial radiation, and those who develop hormonal dysfunction as a consequence of treatment, are at elevated risk of low bone mineral density years after their cancer is cured. A study of nearly 500 pediatric cancer survivors screened with DEXA found that about 8% had low BMD, with the strongest risk factors being male sex, exposure to radiation involving the whole body or brain, and gonadal dysfunction.10PubMed Central / Wiley Online Library. Risk factors and surveillance for reduced bone mineral density in pediatric cancer survivors
For these young survivors, the concern is not that DEXA will detect a recurrence of their cancer. It is that the treatment that saved their life may have left them with a skeleton that is weaker than it should be at their age, putting them at risk for fractures decades earlier than their peers. Long-term survivorship guidelines from pediatric oncology groups include DEXA screening for at-risk patients, recognizing that catching bone loss early allows for interventions like vitamin D supplementation, weight-bearing exercise, and sometimes medication.
Body Composition Monitoring in Cancer Patients
DEXA has a lesser-known capability: it can measure lean tissue mass and fat mass across the whole body, not just bone density. This has become increasingly relevant in oncology because of cancer cachexia, a wasting syndrome involving loss of skeletal muscle and fat that affects a large proportion of patients with advanced cancer and significantly worsens outcomes.
DEXA has been widely used in cachexia research trials as a way to track changes in lean and fat tissue during treatment.11PubMed Central. Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series In clinical practice, though, DEXA is used almost exclusively for bone density, and body composition measurements remain largely a research tool.3Oxford Academic. Imaging modalities for measuring body composition in patients with cancer: opportunities and challenges CT scans performed for routine cancer staging already capture cross-sectional images that can be analyzed for muscle and fat, which has led to growing interest in “opportunistic” body composition assessment from imaging patients are already getting. Still, for dedicated body composition measurement, DEXA remains a reference standard that researchers compare other methods against.
When a DEXA Finding Triggers a Cancer Workup
In practice, a DEXA scan leads to a cancer investigation in a fairly narrow set of circumstances. A radiologist reviewing the images might notice an unusual density pattern, a visible mass, or a vertebral fracture that looks suspicious. A clinician reviewing the BMD numbers might see values that do not match the patient’s risk profile, such as spine readings that are inexplicably high or a single vertebral level that is dramatically lower than its neighbors.
Vertebral fractures deserve special mention. Osteoporosis is the leading cause of non-traumatic vertebral fractures, and many of these fractures go undetected because the symptoms are vague. But not every vertebral fracture is from osteoporosis. Pathologic fractures caused by cancer that has weakened the bone can look similar on basic imaging. When a DEXA scan reveals a vertebral fracture, especially in a patient without known severe osteoporosis, the next step is often an MRI or CT to determine whether the fracture is from garden-variety bone thinning or from something more concerning like metastatic disease or myeloma.
The important thing to understand is that DEXA does not diagnose anything beyond bone density. When it raises a red flag, the response is always additional investigation with more capable imaging and, often, blood work. A suspicious DEXA finding is a starting point, not an endpoint.
Artificial Intelligence and Future Possibilities
One of the more promising developments is the use of AI algorithms to extract more information from DEXA scans than human readers typically capture. The machine-learning study on osteoblastic metastases mentioned earlier is an example: where radiologists caught only about one in six cases, a trained algorithm flagged roughly four in five.5PubMed. Random forest classifiers aid in the detection of incidental osteoblastic osseous metastases in DEXA studies This does not turn DEXA into a cancer-screening tool, but it suggests that AI-assisted reading could catch more incidental findings that warrant follow-up.
Separately, researchers are developing AI tools for “opportunistic screening” on CT scans that patients receive for other reasons, such as lung cancer screening or cardiac calcium scoring. These algorithms can estimate bone mineral density from CT images with strong agreement to DEXA-based measurements.12PubMed Central. Opportunistic AI-enabled automated bone mineral density measurements in lung cancer screening and coronary calcium scoring CT scans are equivalent The idea is to identify osteoporosis in patients who are already getting scanned for something else, reducing the need for a separate DEXA visit. While this is an adjacent development rather than a direct expansion of DEXA’s cancer-detecting abilities, it reflects a broader trend of squeezing more clinical value out of routine imaging through computational analysis.
Common Misconceptions Worth Clearing Up
A few misunderstandings circulate about DEXA scans and cancer that are worth addressing directly.
The first is that a normal DEXA result means your bones are free of cancer. It does not. DEXA measures average density over an area. A small metastatic deposit sitting in one corner of a vertebra may not change the overall reading enough to flag anything unusual. Mixed lytic-and-blastic lesions can even cancel each other out in a density measurement, producing a normal-looking number despite significant disease. And soft-tissue cancers that have not reached bone will not show up on DEXA at all.
The second misconception is that an abnormal DEXA result probably means cancer. For the vast majority of patients, an abnormal DEXA result means osteoporosis or osteopenia, full stop. Cancer-related findings on DEXA are incidental and uncommon. The scan is ordered millions of times a year for routine bone-health screening, and the overwhelming majority of abnormal results reflect age-related bone loss, hormonal changes, medication effects, or nutritional deficiencies.
The third is that DEXA exposes you to concerning radiation. As noted earlier, a whole-body DEXA delivers less radiation than you absorb from natural background sources in a single day. Even in children, where radiation sensitivity is higher, doses from modern DEXA devices remain extremely low, in the range of 4 to 10 microsieverts depending on the machine.8European Radiology. Radiation exposure in X-ray-based imaging techniques used in osteoporosis If your doctor orders repeated DEXA scans to monitor bone health during cancer treatment, the cumulative radiation exposure is negligible compared to a single diagnostic CT scan.
When You Should Actually Worry
If you have had a DEXA scan and your results are flagged as abnormal, the most productive next step is a conversation with your doctor about what kind of abnormality was found. A low T-score at the hip and spine in a 65-year-old woman is textbook osteoporosis and does not suggest cancer. An unexpectedly high reading at one spinal level in a man with known prostate cancer is a different story entirely. A vertebral fracture noted on a lateral spine image in someone who has never been diagnosed with severe osteoporosis warrants further imaging to rule out a pathologic cause.
Context is everything. Your medical history, the pattern of the findings, and the specific numbers all influence whether a DEXA result triggers routine osteoporosis management or a more urgent workup. The scan itself is just a data point, and an intentionally simple one at that. It was built to answer one question well, not to answer every question about your skeleton.